.png)
.png)
Total amount raised
$31.5M
Latest funding date
2025-01-30
Location
Nucleus has successfully navigated three funding rounds, with the most recent being a Series A round supported by 10 investors. The company is backed by 33 investors, including notable names like One Eight Capital and Neo.
Nucleus Genomics has raised a total of approximately $31.5 million across three funding rounds, backed by leading investors including Founders Fund, Seven Seven Six, Neo, One Eight Capital, and Giant Step Capital.
Keep reading to explore Nucleus's fundraising journey, key backers, and what's ahead for this innovative genetic testing company.
What Is Nucleus?
Nucleus, a genetic testing company based in New York, specializes in uncovering health risks and aiding in reproductive health. The company operates within the biotechnology, health care, and pharmaceutical industries.
Founded with a mission to help families have healthy children, Nucleus employs between 11–50 people. Their services include advanced whole-genome sequencing health tests and IVF+ to support reproductive success.
How Much Funding Has Nucleus Raised?
- Seed Round
- Amount Raised: USD 3,500,000
- Date: December 15, 2021
- Lead Investors: Founders Fund
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand genetic testing capabilities and enhance research and development. Notable participants included Adrian Aoun, Brent Saunders, Matteo Franceschetti, Shrug Capital, Quiet Capital, and others.
- Seed+ Round
- Amount Raised: USD 14,000,000
- Date: July 14, 2022
- Lead Investors: Seven Seven Six (Alexis Ohanian)
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To scale operations and expand market reach. Participants included Founders Fund, Hugo Barra, Packy McCormick, Shrug Capital, Alexandra Botez, Anthony Pompliano, and others.
- Series A Round
- Amount Raised: USD 14,000,000
- Date: January 30, 2025
- Lead Investors: Seven Seven Six and Founders Fund (returning investors); new participants include Neo, One Eight Capital, Giant Step Capital, Common Metal, Asylum Ventures, Rose Street Capital, Balaji Srinivasan, and Amanda Bradford
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To capitalize on the growing demand for genetic health innovations, scale whole-genome sequencing, and expand clinical offerings following the acquisition of Irish biotech Cambrean.
Total Amount Raised: USD 31,500,000 (across all disclosed rounds). Current Valuation: Not publicly disclosed.
Key Investors
- Founders Fund
- Details: A venture capital firm known for backing ambitious and often transformative startups, founded by Peter Thiel. Investors in both the 2021 seed round and the 2025 Series A.
- Investment Focus Areas: Technology, healthcare, high-impact sectors.
- Notable Investments: Facebook, SpaceX, Palantir Technologies.
- Seven Seven Six
- Details: A venture capital firm founded by Reddit co-founder Alexis Ohanian. Led the 2022 Seed+ round and returned for the 2025 Series A, having invested over $10 million in Nucleus in total.
- Investment Focus Areas: Early-stage startups across various sectors.
- Notable Investments: Not publicly disclosed.
- Neo
- Details: An investment firm focusing on early-stage technology companies. Participated in the 2025 Series A round.
- Investment Focus Areas: Early-stage technology companies.
- Notable Investments: Not publicly disclosed.
- One Eight Capital
- Details: A New York-based investment firm that joined Nucleus as a new investor in the 2025 Series A round.
- Investment Focus Areas: Healthcare and social impact investing.
- Notable Investments: Not publicly disclosed.
- Giant Step Capital
- Details: A New York-based investment firm that participated in the 2025 Series A round alongside other new investors.
- Investment Focus Areas: Not publicly disclosed.
- Notable Investments: Not publicly disclosed.
What's Next for Nucleus?
Nucleus stands at the forefront of a rapidly evolving genetic testing market, poised to revolutionize preventative healthcare. By integrating wearable data with genetic insights, the company aims to offer a comprehensive view of personal health. The consumer healthcare market, particularly in genomics and personalized medicine, is projected to exceed $30 billion within the next five years, presenting a vast opportunity for growth.
As the cost of genome sequencing continues to decrease, Nucleus is well-positioned to make genetic testing more accessible and affordable. This growing demand suggests potential for future funding rounds to support further research, development, and market expansion. However, the company must navigate challenges such as ensuring the accuracy of their tests, maintaining consumer trust, and addressing ethical concerns related to genetic data privacy.
Use Clay to Get Funding Data
Sales professionals, take advantage of Clay's platform to access comprehensive fundraising data on companies like Nucleus and gather other critical business insights.
Sign up for free to start leveraging these powerful tools and stay ahead in your industry.
